Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcγR scFv on cancer cell surface

[1]  P. Wallace,et al.  Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. , 2001, Journal of immunological methods.

[2]  F. Vély,et al.  Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells. , 2000, Seminars in immunology.

[3]  K. Liao,et al.  Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells , 2000, Gene Therapy.

[4]  L. Weiner,et al.  Bispecific antibodies in cancer therapy. , 1999, Current opinion in immunology.

[5]  T. Logtenberg,et al.  Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. , 1999, Cancer research.

[6]  Michaela A. E. Arndt,et al.  A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. , 1999, Blood.

[7]  H. Geuze,et al.  The FcγRIa (CD64) Ligand Binding Chain Triggers Major Histocompatibility Complex Class II Antigen Presentation Independently of Its Associated FcR γ-Chain , 1999 .

[8]  U. Nielsen,et al.  Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. , 1999, Molecular immunology.

[9]  W. Fridman,et al.  Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties. , 1999, Experimental hematology.

[10]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[11]  M. Pfreundschuh,et al.  Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. , 1998, Leukemia & lymphoma.

[12]  J. Allison,et al.  Enhancement of the anti‐tumor immune response using a combination of interferon‐γ and B7 expression in an experimental mammary carcinoma , 1998, International journal of cancer.

[13]  C. Rugarli,et al.  Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. , 1998, Human gene therapy.

[14]  L. Moretta,et al.  Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. , 1998, Immunology today.

[15]  L. Bracco,et al.  Intracellular Targeting of Oncogenes: A Novel Approach for Cancer Therapy , 1998 .

[16]  W. Fridman,et al.  Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2). , 1997, Hybridoma.

[17]  J. Ting,et al.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Bernard,et al.  Selective isolation of transiently transfected cells from a mammalian cell population with vectors expressing a membrane anchored single-chain antibody. , 1996, Journal of immunological methods.

[19]  P. Wallace,et al.  Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. , 1996, Blood.

[20]  G. Adams,et al.  Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fcγ RIII , 1996, Cancer Immunology, Immunotherapy.

[21]  L. Weiner,et al.  Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII , 1995 .

[22]  J. Fisher,et al.  Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Fridman,et al.  In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody , 1995 .

[24]  R. Foà,et al.  IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. , 1995, Cytokines and molecular therapy.

[25]  E. Tartour,et al.  Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities. , 1994, ImmunoMethods.

[26]  M. Hulett,et al.  Molecular basis of Fc receptor function. , 1994, Advances in immunology.

[27]  J. Galon,et al.  Soluble CD16 binds peripheral blood mononuclear cells and inhibits pokeweed-mitogen-induced responses. , 1993, Blood.

[28]  V. Diehl,et al.  A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo , 1993, International journal of cancer.

[29]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[30]  G. Adams,et al.  A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. , 1993, Cancer research.

[31]  J. Fisher,et al.  Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. , 1992, Journal of immunology.

[32]  P. Anderson,et al.  Signaling function of reconstituted CD16: ζ:γ receptor complex isoforms , 1992 .

[33]  J. Fisher,et al.  Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32). , 1992, Journal of hematotherapy.

[34]  P. Anderson,et al.  Structure and function of the CD16:zeta:gamma complex expressed on human natural-killer cells. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[35]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[36]  D. Munn,et al.  Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor , 1990, The Journal of experimental medicine.

[37]  G. Trinchieri,et al.  Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells , 1988, The Journal of experimental medicine.

[38]  W. Fridman,et al.  Software for the quantitative evaluation of in vitro monoclonal antibody production from ELISA data. , 1987, Journal of immunological methods.

[39]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[40]  S. Wright,et al.  Human neutrophil Fc gamma receptor distribution and structure. , 1982, Proceedings of the National Academy of Sciences of the United States of America.